Comparative Pharmacology
Head-to-head clinical analysis: AEROSEB DEX versus CORTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROSEB DEX versus CORTAN.
AEROSEB-DEX vs CORTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
2 puffs (100 mcg each) intranasally twice daily
5-60 mg orally once daily, titrated to the lowest effective dose. Maintenance: 5-20 mg daily.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life 1.5–2 hours; clinical context: short duration requires multiple daily doses for sustained effect
Renal elimination of unchanged drug accounts for 30-40% of the dose; fecal/biliary elimination is 50-60% as metabolites. Less than 10% is excreted unchanged in feces.
Renal: 80% as metabolites and unchanged drug; biliary/fecal: 20%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid